ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
In the second quarter of 2024, net sales of Qelbree increased 92% year over year to $59.4 million, and total IQVIA prescriptions were 184,342, up 26%.Piper Sandler downgraded Supernus Pharmaceuticals Inc (NASDAQ:SUPN), saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected.
派珀·桑德勒下调了Supernus Pharmicals Inc（纳斯达克股票代码：SUPN）的评级，称返校季Qelbree处方的预期激增并未如预期的那样实现。
"That has us rethinking our assumptions regarding the longer-term (LT) sales/volume growth trajectory of the product," the analyst adds.
分析师补充说：“这让我们重新考虑了对该产品的长期（LT）销售/销量增长轨迹的假设。”
Qelbree (viloxazine) is indicated to treat attention deficit hyperactivity disorder in children and adults.
Qelbree（维洛沙嗪）适用于治疗儿童和成人的注意力缺陷多动障碍。
In the second quarter of 2024, net sales of Qelbree increased 92% year over year to $59.4 million, and total IQVIA prescriptions were 184,342, up 26%.
在2024年第二季度，Qelbree的净销售额同比增长92％，达到5,940万美元，IQVIA处方总额为184,342张，增长26％。
Piper writes that the management's focus on optimizing Qelbree's net economics, such as reducing copay assistance, suggests that future volume growth may be more modest. While initial estimates projected peak sales nearing $500 million, Piper writes that $400 million is a more realistic target.
派珀写道，管理层专注于优化Qelbree的净经济效益，例如减少自付额补助，这表明未来的销量增长可能更为温和。尽管最初的估计预计峰值销售额接近5亿美元，但派珀写道，4亿美元是一个更现实的目标。
The Piper analyst writes that Qelbree is growing and highlights that YTD prescriptions increased 91% in 2023 compared to 2022.
派珀分析师写道，Qelbree正在增长，并强调与2022年相比，2023年年初至今的处方量增长了91％。
Piper has downgraded Supernus Pharmaceuticals to Neutral from Overweight, with a price target of $36, down from $41.
派珀已将Supernus Pharmicals的评级从增持下调至中性，目标股价从41美元下调至36美元。
Quarter-to-date prescriptions have grown by about 1% in the third quarter of 2024 compared to the second quarter, following a 4% increase in the second quarter over the first quarter. In contrast, prescriptions for all ADHD products have declined sequentially by around 2% quarter-to-date in the third quarter.
继第二季度较第一季度增长4％之后，2024年第三季度迄今为止的处方药量与第二季度相比增长了约1％。相比之下，所有注意力缺陷多动障碍产品的处方在第三季度迄今已连续下降了约2％。
A Piper analyst expects volume growth for Qelbree to accelerate during the back-to-school season but anticipates a slower growth trajectory than initially expected, prompting a reassessment of the drug's peak sales potential.
派珀的一位分析师预计，在返校季，Qelbree的销量增长将加速，但预计增长轨迹将低于最初的预期，这促使人们重新评估该药的峰值销售潜力。
In August, the FDA acknowledged the resubmission of the new drug application (NDA) for the company's apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease.
8月，美国食品药品管理局承认重新提交了该公司用于持续治疗帕金森氏病运动波动（OFF发作）的阿扑吗啡输液设备（SPN-830）的新药申请（NDA）。
The resubmission is now filed, with a user fee goal date (PDUFA date) of February 1, 2025.
重新提交的申请现已提交，用户费用目标日期（PDUFA日期）为2025年2月1日。
In April, the FDA issued a Complete Response Letter related to SPN-830, requiring additional information regarding the product quality and the master file for the infusion device.
4月，美国食品和药物管理局发布了与 SPN-830 相关的完整回复信，要求提供有关输液设备产品质量和主文件的更多信息。
Price Action: SUPN stock is down 7.17% at $31.09 at last check Wednesday.
价格走势：周三最后一次检查时，SUPN股价下跌7.17％，至31.09美元。
Photo via Shutterstock
照片来自 Shutterstock
- Chinese EV Manufacturers BYD And Geely Storm Frankfurt Fair As EU Tariffs Threaten To Crimp Their Global EV Push: Report.
- 中国电动汽车制造商比亚迪和吉利冲击法兰克福博览会，因为欧盟的关税有可能抑制其全球电动汽车的发展：报告。
